Onco-Innovations Announces CAD$5 Million Funding Arrangement

Vancouver-based Onco-Innovations Limited has reported the execution of a term sheet with independent institutional investors for a financing arrangement worth approximately CAD$5 million. The company will proceed with the issuance as a non-brokered private placement, bypassing previous plans under the LIFE Exemption. These 6,764,070 units will contain one common share and one common share purchase warrant each at a notional price of CAD$0.7392 per unit.

Closing of the offering is scheduled for around July 15, 2026, pending regulatory approvals. Each warrant permits purchasing a share at CAD$0.90 within three years, with provisions to prevent any single investor from exceeding a 9.99% ownership stake on a partially diluted basis.

The agreement allows investor payments in cash or UK government bonds, with the sharing agreement determining Onco-Innovations' economic interest over 18 monthly tranches based on a benchmark price of CAD$0.9691 per share. Proceeds will accelerate the ONC010 program and support key development stages.